Stout guards of the central nervous system

Science

Volumn 302, Issue 5642, 2003, Pages

  Mechoulam, R ^a   Lichtman, A H ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; ANANDAMIDE REPTAKE INHIBITOR; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABIS; DEXANABINOL; DRONABINOL; GLYCEROL DERIVATIVE; KAINIC ACID; N (3 FURYLMETHYL)ARACHIDONAMIDE; RIMONABANT; UNCLASSIFIED DRUG; 2-ARACHIDONYLGLYCEROL; 4 AMINOBUTYRIC ACID; ACYLGLYCEROL; AMIDE; AMINO ACID RECEPTOR BLOCKING AGENT; AMINO ACID RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ARACHIDONIC ACID DERIVATIVE; CANNABIDIOL; CANNABINOID; CANNABINOID RECEPTOR; CONVULSANT AGENT; DRUG DERIVATIVE; DRUG RECEPTOR; ENDOCANNABINOID; GLUTAMIC ACID; NEUROPROTECTIVE AGENT; TETRAHYDROCANNABINOL;

NERVOUS SYSTEM;

ATAXIA; CENTRAL NERVOUS SYSTEM; CONVULSION; DEPRESSION; DRUG DEPENDENCE; EPILEPSY; HUMAN; NEUROPROTECTION; PRIORITY JOURNAL; REVIEW; ANIMAL; BRAIN; BRAIN DISEASE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GENETICS; METABOLISM; MOUSE; NERVE CELL; NOTE; RAT; SIGNAL TRANSDUCTION;

CANNABIS;

ANIMALS; ANTICONVULSANTS; ARACHIDONIC ACIDS; BRAIN; BRAIN DISEASES; CANNABIDIOL; CANNABINOIDS; CONVULSANTS; ENDOCANNABINOIDS; EPILEPSY; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; GLYCERIDES; HUMANS; KAINIC ACID; MICE; NEURONS; NEUROPROTECTIVE AGENTS; POLYUNSATURATED ALKAMIDES; RATS; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SIGNAL TRANSDUCTION; TETRAHYDROCANNABINOL;

EID: 0141754171     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1091256     Document Type: Review

References (12)

1. R. Mechoulam, in Cannabinolds as Therapeutic Agents, R. Mechoulam, Ed. (CRC Press, Boca Raton, FL, 1986), pp. 1-19.
2. R. Karler, S. A. Turkanis, J. Clin. Pharmacol. 21, 4375 (1981).
3. G. Marsicano et al., Science 302, 84 (2003).
4. R. Mechoulam, M. Spatz, E. Shohami, Sci. STKE 2002, re5 (2002).
5. R. I. Grundy. Expert Opin. Investig. Drugs 11, 1365 (2002).
6. D. Panikashvili et al., Nature 413, 527 (2001).
7. H. H. Hansen et al., J. Neurochem. 78, 1415 (2001).
8. M. van der Stelt et al., J. Neurosci. 21, 8765 (2001).
9. T. Nagayama et al., J. Neurosci. 19, 2987 (1999).
10. A. B. Clement, E. G. Hawkins, A. H. Lichtman, B. F. Cravatt, J. Neurosci. 23, 3916 (2003).
11. H. H. Hansen et al., J. Neurochem. 82, 154 (2002).
12. A. C. Howlett et al., Pharmacol. Rev. 54, 161 (2002).